Teos Therapeutics downgraded to Hold after belrestotug failure and GSK deal ending. Read my updated analysis on ITOS stock ...

Belrestotug plus dostarlimab showed no progression-free survival benefit in NSCLC, leading GSK and iTeos to discontinue all ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston ...